Go offline with the Player FM app!
Targeting Mast Cells: A New Frontier in Allergy & Inflammation with Jasper Therapeutics’ CMO Dr. Edwin Tucker
Manage episode 493515572 series 2900042
In this episode of the Xtalks Life Science Podcast, host Ayesha Rashid speaks with Edwin Tucker, MD, MBA, Chief Medical Officer (CMO) at Jasper Therapeutics, about innovative approaches to treating chronic mast cell diseases such as asthma, food allergies and IBS.
Dr. Tucker has over 30 years of clinical drug development experience, with past roles as CMO at Goldfinch Bio and Mirum Pharmaceuticals, where he led the first FDA approval for Alagille Syndrome. He also served as COO at Acerta Pharma and held leadership positions at Genentech, Janssen and Bayer.
Dr. Tucker is a member of the Royal College of Physicians (UK). He received his MBA from the University of Connecticut and holds degrees in Pharmacology and Medicine from the University of Leeds, UK. Additionally, he serves as a managing director at Golden Seeds, an investment firm dedicated to pursuing early-stage investment opportunities in women-led businesses.
Tune in to learn how Jasper Therapeutics’ work could reshape the landscape for patients with allergic and inflammatory conditions.
For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/
Follow Us on Social Media
Twitter: https://twitter.com/Xtalks
Instagram: https://www.instagram.com/xtalks/
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured
213 episodes
Manage episode 493515572 series 2900042
In this episode of the Xtalks Life Science Podcast, host Ayesha Rashid speaks with Edwin Tucker, MD, MBA, Chief Medical Officer (CMO) at Jasper Therapeutics, about innovative approaches to treating chronic mast cell diseases such as asthma, food allergies and IBS.
Dr. Tucker has over 30 years of clinical drug development experience, with past roles as CMO at Goldfinch Bio and Mirum Pharmaceuticals, where he led the first FDA approval for Alagille Syndrome. He also served as COO at Acerta Pharma and held leadership positions at Genentech, Janssen and Bayer.
Dr. Tucker is a member of the Royal College of Physicians (UK). He received his MBA from the University of Connecticut and holds degrees in Pharmacology and Medicine from the University of Leeds, UK. Additionally, he serves as a managing director at Golden Seeds, an investment firm dedicated to pursuing early-stage investment opportunities in women-led businesses.
Tune in to learn how Jasper Therapeutics’ work could reshape the landscape for patients with allergic and inflammatory conditions.
For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/
Follow Us on Social Media
Twitter: https://twitter.com/Xtalks
Instagram: https://www.instagram.com/xtalks/
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured
213 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.